UNSPSC 51372323: Mirfentanil hydrochloride

This classification denotes an opioid receptor agonist with the molecular formula C22H24N4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4XFQ391SJU, chemically known as 2-furancarboxamide, n-(1-(2-phenylethyl)-4-piperidinyl)-n-pyrazinyl-, monohydrochloride but more generally known as mirfentanil hydrochloride, which bears US NIH Compound Identifier 60697. Most nations, for tariff and trade purposes, schedule mirfentanil hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, MIRFENTANIL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Mirfentanil hydrochloride bears US NLM identifiers UMLS ID C2984002 and NCI Concept Code C91048. SMILES: C1CCC(CC1)CCN2CCC(CC2)N(C3CNCCN3)C(=O)C4CCCO4.CL.

UNSPSC 51372323 Mirfentanil hydrochloride, a Commodity code, shows limited concrete procurement activity aligned with its specific product scope. State and local governments soliciting under this code are acquiring pharmaceutical products — primarily generic multi-source drugs and over-the-counter items — through cooperative purchasing arrangements and competitive bidding processes that emphasize fixed pricing, compliance with FDA and Drug Supply Chain Security Act (DSCSA) requirements, and delivery through authorized wholesalers. The issuing bodies include state health and human services departments, county health systems, and cooperative purchasing alliances serving multiple jurisdictions. Vendors must maintain cGMP certification, hold substantial commercial general liability and professional liability insurance, and comply with E-Verify and drug-free workplace requirements. Contracts typically span two years with optional renewal terms and include probationary periods or performance penalty structures.

Recent activity centers on the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, which posted an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with pricing evaluation weighted 75 percent and all products required available by May 15, 2026 for an effective date of July 1, 2026. Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023) for naloxone and drug deactivation systems with quarterly deliveries to the County Community Health Building. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program as a preliminary market-intelligence phase. The code shows scattered geographic activity across Florida, Minnesota, Oregon, and Texas, though the Mirfentanil hydrochloride commodity itself appears to have minimal recent dedicated solicitation — the indexed opportunities focus on broader pharmaceutical categories rather than this specific controlled substance formulation.